330 related articles for article (PubMed ID: 11039575)
61. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
[TBL] [Abstract][Full Text] [Related]
62. Hereditary breast cancer: a review.
Arver B; Du Q; Chen J; Luo L; Lindblom A
Semin Cancer Biol; 2000 Aug; 10(4):271-88. PubMed ID: 10966850
[TBL] [Abstract][Full Text] [Related]
63. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
Lakhani SR; Gusterson BA; Jacquemier J; Sloane JP; Anderson TJ; van de Vijver MJ; Venter D; Freeman A; Antoniou A; McGuffog L; Smyth E; Steel CM; Haites N; Scott RJ; Goldgar D; Neuhausen S; Daly PA; Ormiston W; McManus R; Scherneck S; Ponder BA; Futreal PA; Peto J; Stoppa-Lyonnet D; Bignon YJ; Stratton MR
Clin Cancer Res; 2000 Mar; 6(3):782-9. PubMed ID: 10741697
[TBL] [Abstract][Full Text] [Related]
64. Identification of a founder BRCA2 mutation in Sardinia.
Pisano M; Cossu A; Persico I; Palmieri G; Angius A; Casu G; Palomba G; Sarobba MG; Rocca PC; Dedola MF; Olmeo N; Pasca A; Budroni M; Marras V; Pisano A; Farris A; Massarelli G; Pirastu M; Tanda F
Br J Cancer; 2000 Feb; 82(3):553-9. PubMed ID: 10682665
[TBL] [Abstract][Full Text] [Related]
65. Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Gayther SA; Ponder BA
Mol Med Today; 1997 Apr; 3(4):168-74. PubMed ID: 9134530
[TBL] [Abstract][Full Text] [Related]
66. BRCA1 and BRCA2 mutations in central and southern Italian patients.
Ottini L; D'Amico C; Noviello C; Lauro S; Lalle M; Fornarini G; Colantuoni OA; Pizzi C; Cortesi E; Carlini S; Guadagni F; Bianco AR; Frati L; Contegiacomo A; Mariani-Costantini R
Breast Cancer Res; 2000; 2(4):307-10. PubMed ID: 11056688
[TBL] [Abstract][Full Text] [Related]
67. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
[TBL] [Abstract][Full Text] [Related]
68. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Tonin PN; Mes-Masson AM; Futreal PA; Morgan K; Mahon M; Foulkes WD; Cole DE; Provencher D; Ghadirian P; Narod SA
Am J Hum Genet; 1998 Nov; 63(5):1341-51. PubMed ID: 9792861
[TBL] [Abstract][Full Text] [Related]
69. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
[TBL] [Abstract][Full Text] [Related]
70. Risk of breast cancer in carriers of BRCA gene mutations.
Whittemore AS
N Engl J Med; 1997 Sep; 337(11):788-9. PubMed ID: 9289641
[No Abstract] [Full Text] [Related]
71. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family.
Nordling M; Karlsson P; Wahlström J; Engwall Y; Wallgren A; Martinsson T
Cancer Res; 1998 Apr; 58(7):1372-5. PubMed ID: 9537232
[TBL] [Abstract][Full Text] [Related]
72. A high proportion of founder BRCA1 mutations in Polish breast cancer families.
Górski B; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Grzybowska E; Mackiewicz A; Stawicka M; Bebenek M; Sorokin D; Fiszer-Maliszewska Ł; Haus O; Janiszewska H; Niepsuj S; Góźdź S; Zaremba L; Posmyk M; Płuzańska M; Kilar E; Czudowska D; Waśko B; Miturski R; Kowalczyk JR; Urbański K; Szwiec M; Koc J; Debniak B; Rozmiarek A; Debniak T; Cybulski C; Kowalska E; Tołoczko-Grabarek A; Zajaczek S; Menkiszak J; Medrek K; Masojć B; Mierzejewski M; Narod SA; Lubiński J
Int J Cancer; 2004 Jul; 110(5):683-6. PubMed ID: 15146557
[TBL] [Abstract][Full Text] [Related]
73. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Górski B; Byrski T; Huzarski T; Jakubowska A; Menkiszak J; Gronwald J; Pluzańska A; Bebenek M; Fischer-Maliszewska L; Grzybowska E; Narod SA; Lubiński J
Am J Hum Genet; 2000 Jun; 66(6):1963-8. PubMed ID: 10788334
[TBL] [Abstract][Full Text] [Related]
74. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
Tonin PN; Mes-Masson AM; Narod SA; Ghadirian P; Provencher D
Clin Genet; 1999 May; 55(5):318-24. PubMed ID: 10422801
[TBL] [Abstract][Full Text] [Related]
75. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.
Petrij-Bosch A; Peelen T; van Vliet M; van Eijk R; Olmer R; Drüsedau M; Hogervorst FB; Hageman S; Arts PJ; Ligtenberg MJ; Meijers-Heijboer H; Klijn JG; Vasen HF; Cornelisse CJ; van 't Veer LJ; Bakker E; van Ommen GJ; Devilee P
Nat Genet; 1997 Nov; 17(3):341-5. PubMed ID: 9354803
[TBL] [Abstract][Full Text] [Related]
76. A low proportion of BRCA2 mutations in Finnish breast cancer families.
Vehmanen P; Friedman LS; Eerola H; Sarantaus L; Pyrhönen S; Ponder BA; Muhonen T; Nevanlinna H
Am J Hum Genet; 1997 May; 60(5):1050-8. PubMed ID: 9150152
[TBL] [Abstract][Full Text] [Related]
77. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
Lancaster JM; Carney ME; Gray J; Myring J; Gumbs C; Sampson J; Wheeler D; France E; Wiseman R; Harper P; Futreal PA
Br J Cancer; 1998 Dec; 78(11):1417-20. PubMed ID: 9836472
[TBL] [Abstract][Full Text] [Related]
78. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families.
Huusko P; Pääkkönen K; Launonen V; Pöyhönen M; Blanco G; Kauppila A; Puistola U; Kiviniemi H; Kujala M; Leisti J; Winqvist R
Am J Hum Genet; 1998 Jun; 62(6):1544-8. PubMed ID: 9585608
[No Abstract] [Full Text] [Related]
79. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
[TBL] [Abstract][Full Text] [Related]
80. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.
Bennett LM; McAllister KA; Malphurs J; Ward T; Collins NK; Seely JC; Gowen LC; Koller BH; Davis BJ; Wiseman RW
Cancer Res; 2000 Jul; 60(13):3461-9. PubMed ID: 10910057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
